Recurrent Malignant Glioma Clinical Trial
Official title:
A Single-center, Single-arm, Open-label Phase 1 Clinical Trial to Assess the Safety and Tolerability of YYB-103, IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell (CAR-T) in Treating Patients With Refractory or Recurrent Malignant Glioma
Verified date | September 2022 |
Source | CellabMED |
Contact | Sungmin Jun |
Phone | +82262048381 |
smjun[@]cellabmed.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the changes of AE incidence. And this study have to long term follow-up.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | April 30, 2024 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 74 Years |
Eligibility | Inclusion Criteria 1. Primary inclusion criteria (Screening criteria) : Only subjects who meet all of the following conditions conduct examinations and tests including the IHC and PBMC - Provision of voluntary written consent to participate in this clinical trial - Male and female aged = 19 years to <75 years - Patients with histologically or cytologically confirmed progressive malignant glioma (Grade III or IV according to the WHO criteria) and histological and/or radiologic data to confirm that it is refractory or recurrent (applicable to 'Progression Disease (PD)' according to the Response Assessment for Neuro-Oncology (RANO) criteria for high grade gliomas defined by the Society for Neuro-Oncology) despite treatment applicable to the standard treatment for each stage - Subject with the Karnofsky Performance Status (KPS) Scale = 60 - Subject with the life expectancy of least 12 weeks at the investigator's discretion - Subject who satisfies the following treatment condition, regardless of the previous line of treatment - At least 12 weeks after completion of the last anticancer radiation treatment - Other cell toxicity therapy not mentioned above: At least 3 weeks have passed - Non-cytotoxic agent (e.g., interferon, tamoxifen, etc.): At least 1 week has passed - Completion of treatment of all toxicities and AEs (other than alopecia and vitiligo) due to the previous treatment 2. Secondary Inclusion Criteria (Eligibility Criteria) - Subjects confirmed as positive for IL13Ra2 expression from immunostaining (IHC) - Subjects with Peripheral Blood Monocyte Count = 7.5x10^5 cells/5 ml from the PBMC test - Subjects with appropriate bone marrow, liver, and kidney function by satisfying all of the following in clinical laboratory tests - WBC = 2,000/µl - ANC = 1,000/µl - Platelet count = 75,000/µl - Hemoglobin = 8.0 g/dL - ALT/AST = 2.5 x ULN - Serum creatinine = 1.5 x ULN - Total bilirubin = 1.5 x ULN Exclusion Criteria 1. Primary Exclusion Criteria (Screening criteria) - Subjects diagnosed with ventricular seeding, spinal drop metastasis, or leptomeningeal metastasis from radiologic testing obtained at screening - Subjects with findings of immunodeficiency, autoimmune disease (e.g.; rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, etc.) or inflammatory disease - Subjects with significant active cardiovascular disease including the following - Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg), unstable angina, pulmonary embolism, cerebrovascular disease, valvular disease, cardiac failure, or myocardial infarction or serious cardiac arrhythmia within the past 6 months - Subjects with a medical history of malignant tumor other than the study indication within 5 years of screening (however, within 3 years of screening in case of malignant tumor (e.g., appropriately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ, etc.) with minimal risk of metastasis/recurrence and death) - Subjects who continuously used systemic immunosuppressants (including but not limited to cyclophosphamide, azathioprine, methotrexate, and thalidomide) other than steroids within 2 weeks of screening - Subjects on systemic steroids who received a dose exceeding dexamethasone 6 mg/day (or equivalent dose) within 1 week of screening(note that topical steroids, inhaled steroid, and use of transient steroids for prevention of vomiting prior to anticancer agents administration are acceptable) - Subjects with a history of previously using an immune cell therapy agent - Subjects with a medical history of severe allergy, anaphylaxis, or other hypersensitivity reaction to the chimeric or humanized antibody or fusion protein - Subjects who participated in other clinical trial (medicinal product or medical device) within 4 weeks of screening - Women of childbearing potential and men who have a plan to get pregnant until 3 months after investigational product administration, are not willing to practice appropriate contraception method*, or are not willing to maintain abstinence from sexual intercourse * Hormonal contraception method, intrauterine device (IUD) or intrauterine system (IUS), surgical sterilization of the subject or partner, tubal ligation, double barrier method (a combined use of a barrier method such as a female condom, cervical cap, contraceptive diaphragm, or contraceptive sponge with a male condom), single barrier method combined with spermicide) - Pregnant women or breastfeeding mothers - Subjects who are determined by the investigator to be ineligible as subjects of this clinical trial for other reason 2. Secondary Exclusion Criteria (Eligibility Criteria) - Subjects who are positive to any of the following virus test results at screening - Hepatitis B virus surface antigen (HBsAg) - Hepatitis C virus antibody test (anti-HCV Ab) - HIV antibody test (anti-HIV) - Subjects who are determined by the investigator to be ineligible as subjects of this clinical trial for other reason |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | National Cancer Center, Korea | Goyang-si | Gyeonggi |
Lead Sponsor | Collaborator |
---|---|
CellabMED |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Limiting Toxicity (DLT) | 28 days after IP administration | ||
Primary | Maximum Tolerance Dose (MTD) | 28 days after IP administration | ||
Primary | Recommended Phase 2 Dose (RP2D) | 28 days after IP administration | ||
Secondary | Incidence of AE | CRS and ICANS (ASTCT) / Others (CTCAE V5.0) | 3 months, up to 15 years if necessary | |
Secondary | RCR | RCR formation will be checked by collecting samples at 3M, 6M, and every 6 months thereafter until 5 years from IP administration, and then will be followed up annually thereafter until 15 years from IP administration via medical history without collecting samples. If all RCR test results are negative for 1 year after IP administration, sample collection will be stopped, and annual follow-up. | 1 year, up to 15 years if necessary | |
Secondary | Pharmacokinetics and cytokine levels | Peripheral blood (PB) and Cerebral spinal fluid (CSF) | 3 months, up to 15 years if necessary | |
Secondary | Disease response (DCR) | Tumor response will be assessed by comparison with baseline magnetic resonance imaging by iRANO criteria. Evaluation of DCR is the proportion of subjects with CR or PR or SD as a result of tumor response assessment. | Baseline up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT03598244 -
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
|
Phase 1 | |
Recruiting |
NCT05278208 -
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04320888 -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT05139056 -
Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02208362 -
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
|
Phase 1 | |
Active, not recruiting |
NCT02192359 -
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Unknown status |
NCT01144988 -
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
|
Phase 2 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT04388475 -
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT04195555 -
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT01904123 -
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
|
Phase 1 | |
Active, not recruiting |
NCT02658279 -
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
|
N/A | |
Withdrawn |
NCT04521946 -
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
|
Phase 1 | |
Recruiting |
NCT04214392 -
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Recruiting |
NCT03896568 -
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
|
Phase 1 | |
Active, not recruiting |
NCT01672463 -
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
|
Phase 1 |